ClinicalTrials.gg

TargetBeta

C5

complement C5 · also CPAMD4, C5a, C5b · Receptor ligands

8 programs in company-led studies act on C5, from 6 companies: 4 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (7 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
ravulizumabruleAstraZenecaphase 4359 running–ChEMBL
pozelimabruleRegeneron Pharmaceuticalsphase 4145 running–ChEMBL
eculizumabruleAstraZenecaphase 4381 running–ChEMBL
CrovalimabruleHoffmann-La Rochephase 3105 running–ChEMBL
cemdisiranruleRegeneron Pharmaceuticalsphase 3104 running–NCIt
zilucoplanruleUCBphase 3143 running–ChEMBL
vilobelimabruleInflaRxphase 3132 running–NCIt
ABBV-6628AbbViephase 211 running–the company's pipeline

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.